Nucleix Secures $55 Million Funding Led by RA Capital Management and Additional Prominent Life Science Investors to Advance Lung EpiCheck® for Early Detection of Lung Cancer

SAN DIEGO & REHOVOT, Israel–(BUSINESS WIRE)–Nucleix, a liquid biopsy company revolutionizing cancer treatment by detecting the disease earlier, has secured $55 million from a syndicate of leading life science investors in an oversubscribed financing round.

Subscribe to one of our social media channels